Diane Brisson

List of Publications by Year
in descending order

28 papers	757 citations	567281 15 h-index	526287 27 g-index
28 all docs	28 docs citations	28 times ranked	1448 citing authors

#	Article	IF	Citations
1	Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry. Canadian Journal of Cardiology, 2022, 38, 311-319.	1.7	7
2	Palmar Striated Xanthomas in Clinical Practice. Journal of the Endocrine Society, 2022, 6, .	0.2	0
3	Non-Alcoholic Fatty Liver in Patients with Chylomicronemia. Journal of Clinical Medicine, 2021, 10, 669.	2.4	11
4	Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia. Journal of Clinical Medicine, 2021, 10, 64.	2.4	9
5	Lomitapide for treatment of homozygous familial hypercholesterolemia: The QuÃ©bec experience. Atherosclerosis, 2020, 310, 54-63.	0.8	12
6	Association of common gene-smoking interactions with elevated plasma apolipoprotein B concentration. Lipids in Health and Disease, 2020, 19, 98.	3.0	1
7	Dissection of Clinical and Gene Expression Signatures of Familial versus Multifactorial Chylomicronemia. Journal of the Endocrine Society, 2020, 4, bvaa056.	0.2	14
8	Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. Expert Opinion on Drug Discovery, 2020, 15, 403-414.	5.0	3
9	Gene expression profiles of recurrent acute pancreatitis risk in patients with sustained chylomicronemia. Endocrine Journal, 2020, 67, 1157-1161.	1.6	3
10	Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia. Expert Opinion on Drug Safety, 2019, 18, 403-414.	2.4	16
11	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical Chemistry, 2018, 64, 355-362.	3.2	47
12	Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1210-1214.	1.7	62
13	Association study between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and metabolic syndrome. BMC Medical Genetics, 2018, 19, 130.	2.1	1
14	Placental DNA Methylation Adaptation to Maternal Glycemic Response in Pregnancy. Diabetes, 2018, 67, 1673-1683.	0.6	42
15	Large-scale deletions of the ABCA1 gene in patients with hypoalphalipoproteinemia. Journal of Lipid Research, 2018, 59, 1529-1535.	4.2	22
16	Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia. European Heart Journal, 2017, 38, ehw135.	2.2	38
17	Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE. Journal of Clinical Lipidology, 2017, 11, 1161-1167.e3.	1.5	42
18	Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis. Human Gene Therapy, 2016, 27, 916-925.	2.7	75

#	Article	IF	Citations
19	Association between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and hypertension. Hypertension Research, 2016, 39, 467-474.	2.7	6
20	Influence of Abdominal Obesity on the Lipid-Lipoprotein Profile in Apoprotein E2/4 Carriers: The Effect of an Apparent Duality. Journal of Lipids, 2015, 2015, 1-10.	4.8	10
21	Epipolymorphisms within lipoprotein genes contribute independently to plasma lipid levels in familial hypercholesterolemia. Epigenetics, 2014, 9, 718-729.	2.7	57
22	The potential applications of Apolipoprotein E in personalized medicine. Frontiers in Aging Neuroscience, 2014, 6, 154.	3.4	40
23	The Lipid Accumulation Product for the Early Prediction of Gestational Insulin Resistance and Glucose Dysregulation. Journal of Women's Health, 2013, 22, 362-367.	3.3	10
24	Adaptations of placental and cord bloodABCA1ÂDNA methylation profile to maternal metabolic status. Epigenetics, 2013, 8, 1289-1302.	2.7	86
25	The "hypertriglyceridemic waist" phenotype and glucose intolerance in pregnancy. Cmaj, 2010, 182, E722-E725.	2.0	33
26	Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics. Pharmacogenetics and Genomics, 2010, 20, 742-747.	1.5	20
27	Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia. Atherosclerosis, 2008, 196, 262-269.	0.8	18
28	Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics and Genomics, 2002, 12, 313-320.	5.7	72